Results 251 to 260 of about 726,516 (374)

Advances in the Treatment of Diabetic Retinopathy with Anti-VEGF Therapy

open access: hybrid
M.P. González García   +9 more
openalex   +2 more sources

Targeting VEGF and Its Receptors for the Treatment of Osteoarthritis and Associated Pain

open access: yesJournal of Bone and Mineral Research, 2016
J. L. Hamilton   +5 more
semanticscholar   +1 more source

PARPi Combining Nanoparticle LIN28B siRNA for the Management of Malignant Ascites

open access: yesAdvanced Science, EarlyView.
This study demonstrates that co‐inhibition of LIN28B and PARP using siLin28b/DSSP@lip‐PEG‐FA nanoparticles in combination with the PARP inhibitor BMN673 effectively suppresses the accumulation of malignant ascites associated with advanced cancers.
Yan Fang   +13 more
wiley   +1 more source

Hypoxia and VEGF mRNA Expression in Human Tumors

open access: gold, 2001
Lisa S. Ziemer   +5 more
openalex   +1 more source

A Hydrodynamic Bioreactor for High‐Yield Production of Extracellular Vesicles from Stem Cell Spheroids with Defined Cargo Profiling

open access: yesAdvanced Science, EarlyView.
This study harnesses hydrodynamic flows to generate, confine and stimulate stem cell spheroids, enabling the large‐scale production of extracellular vesicles (EVs). This innovative method not only streamlines spheroid formation and subsequent EV release in a single, integrated process, but also ensures the generation of EVs with enhanced biological ...
Solène Lenoir   +7 more
wiley   +1 more source

LMO7 Suppresses Tumor‐Associated Macrophage Phagocytosis of Tumor Cells Through Degradation of LRP1

open access: yesAdvanced Science, EarlyView.
LMO7 in tumor‐associated macrophages suppresses phagocytosis of tumor cells and limits cytotoxic T lymphocytes infiltration, fostering tumor progression. Mechanistically, LMO7 mediates the ubiquitination and degradation of the phagocytic receptor LRP1, impairing its ability to engulf tumor cells and driving macrophages toward an antitumor phenotype ...
Mengkai Li   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy